RU2021117886A - MONTELUKAST FOR THE TREATMENT OF EROSIVE OSTEOARTHRITIS OF THE HAND - Google Patents

Claims (17)

1. The use of montelukast or a pharmaceutically acceptable salt thereof for the treatment of erosive osteoarthritis of the hand in a human subject. 2. Use of a pharmaceutically acceptable salt of montelukast for the treatment of erosive osteoarthritis of the hand in a human subject. 3. The use of a pharmaceutically acceptable salt of montelukast according to claim 2, wherein the pharmaceutically acceptable salt of montelukast is selected from an alkali metal salt or an alkaline earth metal salt, and preferably the salt is sodium montelukast. 4. The use of montelukast or its pharmaceutically acceptable salt according to any one of paragraphs. 1-3, characterized in that montelukast or its pharmaceutically acceptable salt is intended for oral administration. 5. The use of montelukast or its pharmaceutically acceptable salt according to claim 4, characterized in that the dose of montelukast or its pharmaceutically acceptable salt is from 1 to 200 mg/day, expressed as an equivalent dose of montelukast. 6. The use of montelukast or its pharmaceutically acceptable salt according to claim 5, characterized in that the dose of montelukast or its pharmaceutically acceptable salt is from 5 to 15 mg/day, preferably from 7 to 13 mg/day, more preferably from 9 and 11 mg /day, and even more preferably the dose is about 10 mg/day, expressed as an equivalent dose of montelukast. 7. The use of montelukast or its pharmaceutically acceptable salt according to claim 5, characterized in that the dose of montelukast or its pharmaceutically acceptable salt is from 7 to 25 mg/day, preferably from 10 to 20 mg/day, more preferably from 14 and 16 mg /day, and even more preferably the dose is about 15 mg/day, expressed as an equivalent dose of montelukast. 8. The use of montelukast or its pharmaceutically acceptable salt according to claim 5, characterized in that the dose of montelukast or its pharmaceutically acceptable salt is from 10 to 30 mg/day, preferably from 15 to 25 mg/day, more preferably 19-21 mg/day day, and even more preferably the dose is about 20 mg/day, expressed as an equivalent dose of montelukast. 9. The use of montelukast or its pharmaceutically acceptable salt according to claim 5, characterized in that the dose of montelukast or its pharmaceutically acceptable salt is from 15 to 45 mg/day, preferably from 25 to 35 mg/day, more preferably from 29 and 31 mg /day, and even more preferably the dose is about 30 mg/day, expressed as an equivalent dose of montelukast. 10. The use of montelukast or its pharmaceutically acceptable salt according to any one of paragraphs. 1-3, characterized in that montelukast or its pharmaceutically acceptable salt is intended for topical use. 11. The use of montelukast or its pharmaceutically acceptable salt according to any one of paragraphs. 1-3, characterized in that montelukast or its pharmaceutically acceptable salt is in the form of a pharmaceutical composition containing montelukast or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient and/or carrier. 12. The use of montelukast or a pharmaceutically acceptable salt thereof according to claim 11, characterized in that montelukast or a pharmaceutically acceptable salt thereof is in the form of a solid pharmaceutical composition for oral administration selected from the group consisting of tablets, capsules, powders or granules. 13. The use of montelukast or its pharmaceutically acceptable salt according to claim 12, characterized in that the powders or granules are in the form of a single-dose sachet, and that each tablet, capsule, single-dose sachet with powder or granules contains a dose of montelukast or its pharmaceutically acceptable salt in the range of 1 -200 mg expressed as an equivalent dose of montelukast. 14. The use of montelukast or a pharmaceutically acceptable salt thereof according to claim 11, characterized in that montelukast or a pharmaceutically acceptable salt thereof is in the form of a topical pharmaceutical composition, preferably selected from the group consisting of cream, gel, ointment and paste. 15. The use of montelukast or its pharmaceutically acceptable salt according to claim 14, characterized in that the amount of montelukast or its pharmaceutically acceptable salt in the composition is in the range of 0.5-50% by weight, expressed as an equivalent amount of montelukast relative to the total weight of the composition. 16. A method of treating erosive osteoarthritis of the hands, comprising the step of administering to a patient in need of such treatment an effective amount of montelukast or a pharmaceutically acceptable salt thereof. 17. The use of montelukast or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of erosive osteoarthritis of the hand in a human subject.